These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1352099)

  • 1. Expression of sialylated Lewis(x) antigen in chronic and neoplastic liver diseases.
    Jagirdar J; Thung SN; Shah KD; Nudelman E; Singhal A; Paronetto F
    Arch Pathol Lab Med; 1992 Jun; 116(6):643-8. PubMed ID: 1352099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous expression of Lewis Y antigen in clustered hepatocytes in chronic viral, autoimmune, and alcoholic liver diseases but not in biliary diseases.
    Sasaki M; Kono N; Nakanuma Y
    Mod Pathol; 1994 Apr; 7(3):339-46. PubMed ID: 8058706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatic neoductules].
    Fischer HP; Meybehm M; Zhou H; Schoch J
    Verh Dtsch Ges Pathol; 1995; 79():36-46. PubMed ID: 8600693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-group-related antigen Lewis(x) and Lewis(y) in the differential diagnosis of cholangiocarcinoma and hepatocellular carcinoma.
    Jovanovic R; Jagirdar J; Thung SN; Paronetto F
    Arch Pathol Lab Med; 1989 Feb; 113(2):139-42. PubMed ID: 2537068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas.
    Lai YS; Thung SN; Gerber MA; Chen ML; Schaffner F
    Arch Pathol Lab Med; 1989 Feb; 113(2):134-8. PubMed ID: 2464975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sialyl Lewis X expression in hepatocarcinogenesis: potential predictor for the emergence of hepatocellular carcinoma.
    Fujiwara Y; Shimada M; Takenaka K; Kajiyama K; Shirabe K; Sugimachi K
    Hepatogastroenterology; 2002; 49(43):213-7. PubMed ID: 11941958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Lewis blood group antigens in cancerous and non-cancerous liver.
    Kanai T; Hirohashi S; Upton MP; Ino Y; Shimosato Y
    Jpn J Cancer Res; 1987 Sep; 78(9):968-76. PubMed ID: 2822639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD 34 expression in chronic and neoplastic liver diseases.
    Di Carlo I; Fraggetta F; Lombardo R; Azzarello G; Vasquez E; Puleo S
    Panminerva Med; 2002 Dec; 44(4):365-7. PubMed ID: 12434120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assay of the carcinoembryonic antigen (CEA) in acute and chronic liver diseases and hepatocellular carcinoma].
    Piantino P; Gallo V; Pecchio F; Garlanda PF; Bonardi O
    Minerva Med; 1981 Apr; 72(17):1059-64. PubMed ID: 6262678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of proliferating ductular structures in liver disease. An immunohistochemical study.
    Thung SN
    Arch Pathol Lab Med; 1990 Apr; 114(4):407-11. PubMed ID: 1690977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver.
    Brunt EM; Swanson PE
    Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S53-61. PubMed ID: 1374219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of HBs antigen in livers revealed by orcein staining.
    Nakaso S; Sakurai M
    Hepatogastroenterology; 1982 Feb; 29(1):9-12. PubMed ID: 6178673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicology and Carcinogenesis Studies of Furan (CAS No. 110-00-9) in F344 Rats and B6C3F1 Mice(Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Jan; 402():1-286. PubMed ID: 12621516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A liver-specific antigen in the serum of patients with liver disease].
    Rosenmund A
    Schweiz Med Wochenschr; 1971 Jul; 101(28):1023-6. PubMed ID: 5003908
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of bile ducts in primary biliary cirrhosis and other liver diseases by immunohistochemical demonstration of Lewis(a) or b antigen.
    Fritz P; Pedal I; Oeffinger B; Tuczek HV; Wagner T; Rühl U; Romen A; Bader H
    Zentralbl Pathol; 1994 Nov; 140(4-5):299-307. PubMed ID: 7826978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease.
    Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G
    Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orcein-positive hepatitis B surface antigen and liver carcinoma: their association in an Eastern US population.
    Keshgegian AA; Ochs RH
    Arch Pathol Lab Med; 1981 Apr; 105(4):190-3. PubMed ID: 6163416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
    Haglund C; Lindgren J; Roberts PJ; Nordling S
    Br J Cancer; 1991 Mar; 63(3):386-9. PubMed ID: 1848439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of liver-specific antigen in adult human serum.
    Smith JB; Iverson GM
    Clin Exp Immunol; 1973 Feb; 13(2):209-12. PubMed ID: 4120851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.